ConductScience.org, home

Paper17523848

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Wilson WR and 5 others. Radiat Res, 2007. Cited by 55 papers, by iCite.

Cite this record

ConductScience Library. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Papers, record 17523848. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17523848

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
PubMed
Journal
Radiat Res
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
55
iCite
Relative citation ratio, by iCite
1.4
iCite
Revised in PubMed
2007-12-03
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wilson WRWilliam R
2Hicks KOKevin O
3Pullen SMSusan M
4Ferry DMDianne M
5Helsby NANuala A
6Patterson AVAdam V

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bystander EffectMajor topic
Cell HypoxiaMajor topic
Cell SurvivalMajor topic
Lung NeoplasmsMajor topic
Nitrogen Mustard CompoundsMajor topic
Antineoplastic Agents, Alkylating
Cell Line, Tumor
Dose-Response Relationship, Drug
Dose-Response Relationship, Radiation
Feasibility Studies
Humans
Oxidation-Reduction
Prodrugs
Radiation Dosage
Radiation Tolerance

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CA82566NCI NIH HHSUnited StatesP01CA082566PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.

PMIDTitleJournalYearIn PapersSource
41476118PISTOL MRI allows noninvasive assessment of changes in tumor oxygenation post hypoxia targeted therapy.Sci Rep2025https://conductscience.org/library/papers/41476118PubMed
39750141Versatile Stimuli-Responsive Controlled Release of Pinanediol-Caged Boronic Esters for Spatiotemporal and Nitroreductase-Selective Glucose Bioimaging.ACS Sens2025https://conductscience.org/library/papers/39750141PubMed
34625504Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.Mol Cancer Ther2021https://conductscience.org/library/papers/34625504PubMed
34326502Therapeutic targeting of the hypoxic tumour microenvironment.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/34326502PubMed
34245333Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.Cancer Chemother Pharmacol2021https://conductscience.org/library/papers/34245333PubMed
33897898Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy.Theranostics2021https://conductscience.org/library/papers/33897898PubMed
33558701Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.Cancer Gene Ther2022https://conductscience.org/library/papers/33558701PubMed
33105798Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.Molecules2020https://conductscience.org/library/papers/33105798PubMed
32929365E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications.Theranostics2020https://conductscience.org/library/papers/32929365PubMed
31337055Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.Cells2019https://conductscience.org/library/papers/31337055PubMed
30734002Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.Clin Transl Radiat Oncol2019https://conductscience.org/library/papers/30734002PubMed
30591421An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.Neoplasia2019https://conductscience.org/library/papers/30591421PubMed
30575832Hypoxia-targeted drug delivery.Chem Soc Rev2019https://conductscience.org/library/papers/30575832PubMed
30279659Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.Front Pharmacol2018https://conductscience.org/library/papers/30279659PubMed
29423880Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.Bull Math Biol2019https://conductscience.org/library/papers/29423880PubMed
27070712Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Br J Cancer2016https://conductscience.org/library/papers/27070712PubMed
24409417Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Front Oncol2013https://conductscience.org/library/papers/24409417PubMed
24109591The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Front Oncol2013https://conductscience.org/library/papers/24109591PubMed
23758947Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.Mol Cancer2013https://conductscience.org/library/papers/23758947PubMed
21836632Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.Cancer Gene Ther2011https://conductscience.org/library/papers/21836632PubMed

See all 24 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
POR5447PubTator's text mininghttps://conductscience.org/library/genes/5447

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17523848

GET https://conductscience.org/api/papers/v1/17523848/cited_by?page=2